MD Anderson Cancer: Atezolizumab and Bevacizumab Show Meaningful Responses for Malignant Peritoneal Mesothelioma Patients
July 15, 2021
July 15, 2021
HOUSTON, Texas, July 15 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on July 14, 2021:
* * *
Study shows 40% objective response rate for rare cancer with few treatment options
* * *
A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response ra . . .
* * *
Study shows 40% objective response rate for rare cancer with few treatment options
* * *
A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response ra . . .